Characterization of airflow properties of the mometasone furoate dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler® Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014